Navigation Links
Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
Date:5/26/2009

WELLESLEY HILLS, Mass., May 26 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that there has been promising initial interest from pharma companies in the intellectual property of Prospect Therapeutics, Inc. ("Prospect").

In preclinical studies, GCS-100 inhibited blood vessel formation in a variety of cancer models. Development and growth of solid tumors requires new blood vessel growth, or angiogenesis, to deliver oxygen and nutrients to a tumor. Galectin-3 also plays an important role in stimulating angiogenesis in a variety of tissues.

The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction on Monday, June 29, 2009 at 12:00 noon.

Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.

About Prospect Therapeutics, Inc.

Prospect's lead product candidate, GCS-100, is a carbohydrate molecule designed to inhibit the activity of Galectin-3, a protein found in high concentration in a broad range of human cancers and whose over-expression is associated with poor prognosis in cancer patients.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignment for the Benefit of Creditors in the biotech field was Spherics, Inc. and ActivBiotics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@earthlink.net or visit the website at www.finnwarnkegayton.com.


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. HealthCore Responds to Need for Real-world Health Outcomes Information on Drugs and Devices with Physician Network and Prospective Effectiveness Research
2. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
3. Publication of Supplementary Prospectus
4. Pro Football Prospects Training at TEST Sports Clubs(TM) Use SURGEX(TM) as Part of Their Pre-Combine Training Regime
5. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
6. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
7. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
8. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
10. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
11. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 This report analyzes ... Product Segments: Acid Based (Humic, Amino, & Fulvic), Extract Based, ... the following Crop Types: Ornamental & Turf, Row Crops, and ... Canada , Japan , ... Latin America , and Rest of World. ...
(Date:12/8/2016)... Dec. 8, 2016  Biotheranostics today announced that ... of the Breast Cancer Index (BCI) in identifying ... are most at-risk for disease recurrence and might ... from three studies advancing the understanding of the ... tumor biology and inform decisions related to patient ...
(Date:12/8/2016)... December 8, 2016 ... Molekulargenetik, erweitert seine Palette an anpassbaren SureSeq™ NGS-Panels ... FH Panels, das ein schnelles und kostengünstiges Studium ... Panel bietet eine Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide ... einem einzigen kleinen Panel und ermöglicht eine individuelle ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... finalists in the World Technology Awards. uBiome is one of just six company ... all categories. , In addition to uBiome, companies nominated as finalists in this ...
Breaking Biology Technology:
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
Breaking Biology News(10 mins):